Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCORI Critics Emerge As Institute Formally Releases Draft Methods Report

Executive Summary

As the Patient-Centered Outcomes Research Institute opens up the public comment period for the draft report created by the institute’s Methodology Committee, criticisms on the direction PCORI is moving are beginning to surface, including accusations that it is becoming just another AHRQ or NIH.

You may also be interested in...

A New Framework For Comprehensive Evidence Development

In today’s health care environment, where the volume and complexity of clinical information continues to increase for a range of stakeholders, research sponsors must understand how clinical trials, prospective observational research or registries, and retrospective data are used, what the costs are, and what a combined approach will look like. They must prepare for a more comprehensive and efficient research paradigm that provides payors, providers, and policy makers with the requisite data to make coverage and treatment decisions.

PCORI Final Methods Report Will Detail Public Input, Institute’s Response

Drug manufacturers had requested that PCORI list public comments and the Methodology Committee responses in the report, which will establish some of the criteria for reviewing institute research funding applications.

OMOP May Seek To Partner With Mini-Sentinel On Drug Safety, PCORI On Outcomes Research

The drug industry-funded Observational Medical Outcomes Partnership may seek collaboration with high-profile public-private drug safety and comparative effectiveness research initiatives.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts